Masimo Co. (NASDAQ:MASI) Receives $194.80 Average Target Price from Analysts

Shares of Masimo Co. (NASDAQ:MASI) have been given an average recommendation of “Moderate Buy” by the six research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $194.80.

A number of equities analysts have weighed in on MASI shares. Piper Sandler upped their price target on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Raymond James raised their price target on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Thursday, April 10th. Finally, Wells Fargo & Company upped their price objective on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th.

Insider Buying and Selling at Masimo

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the sale, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This represents a 11.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the transaction, the chief operating officer now owns 24,172 shares of the company’s stock, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. 16.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MASI. Jones Financial Companies Lllp bought a new position in Masimo in the fourth quarter worth about $27,000. UMB Bank n.a. raised its position in shares of Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 123 shares during the period. Blue Trust Inc. lifted its holdings in shares of Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 71 shares during the last quarter. Trust Co. of Vermont acquired a new position in Masimo during the 4th quarter valued at approximately $33,000. Finally, Farther Finance Advisors LLC grew its stake in Masimo by 128.9% during the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 116 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Price Performance

MASI opened at $152.06 on Friday. The company has a 50 day moving average of $169.55 and a two-hundred day moving average of $164.54. Masimo has a 52-week low of $101.61 and a 52-week high of $194.88. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a market cap of $8.22 billion, a P/E ratio of 104.87 and a beta of 1.28.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. On average, analysts expect that Masimo will post 4.1 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.